FDA Fast-Tracks Iza-bren for EGFR-Mutant Lung Cancer: A First-in-Class Therapy Aiming to Redefine Treatment for Patients Who Have Exhausted Options
By Team VOH
Bristol Myers Squibb and SystImmune announced that the US FDA has granted breakthrough therapy designation